Planimetric and Volumetric Brainstem MRI Markers in Progressive Supranuclear Palsy, Multiple System Atrophy, and Corticobasal Syndrome. A Systematic Review and Meta-Analysis

Overview

Journal Neurol Int

Publisher MDPI

Specialty Neurology

Date 2024 Feb 23

PMID 38392951

Authors

Maria-Evgenia Brinia

Ioanna Kapsali

Nikolaos Giagkou

Vasilios C Constantinides

Affiliations

Soon will be listed here.

Abstract

Background: Various MRI markers-including midbrain and pons areas (M, P) and volumes (M, P), ratios (M/P, M/P), and composite markers (magnetic resonance imaging Parkinsonism Indices 1,2; MRPI 1,2)-have been proposed as imaging markers of Richardson's syndrome (RS) and multiple system atrophy-Parkinsonism (MSA-P). A systematic review/meta-analysis of relevant studies aiming to compare the diagnostic accuracy of these imaging markers is lacking.

Methods: Pubmed and Scopus were searched for studies with >10 patients (RS, MSA-P or CBS) and >10 controls with data on M, P, M, P, M/P, M/P, MRPI 1, and MRPI 2. Cohen's , as a measure of effect size, was calculated for all markers in RS, MSA-P, and CBS.

Results: Twenty-five studies on RS, five studies on MSA-P, and four studies on CBS were included. Midbrain area provided the greatest effect size for differentiating RS from controls (Cohen's = -3.10; < 0.001), followed by M/P and MRPI 1. MSA-P had decreased midbrain and pontine areas. Included studies exhibited high heterogeneity, whereas publication bias was low.

Conclusions: Midbrain area is the optimal MRI marker for RS, and pons area is optimal for MSA-P. M/P and MRPIs produce smaller effect sizes for differentiating RS from controls.

Citing Articles

Automated brain segmentation and volumetry in dementia diagnostics: a narrative review with emphasis on FreeSurfer.

Khadhraoui E, Nickl-Jockschat T, Henkes H, Behme D, Muller S Front Aging Neurosci. 2024; 16:1459652.

PMID: 39291276 PMC: 11405240. DOI: 10.3389/fnagi.2024.1459652.

Faster, More Practical, but Still Accurate: Deep Learning for Diagnosis of Progressive Supranuclear Palsy.

Mohajer B Radiol Artif Intell. 2024; 6(3):e240181.

PMID: 38691010 PMC: 11140513. DOI: 10.1148/ryai.240181.

References

Quattrone A, Caligiuri M, Morelli M, Nigro S, Vescio B, Arabia G . Imaging counterpart of postural instability and vertical ocular dysfunction in patients with PSP: A multimodal MRI study. Parkinsonism Relat Disord. 2019; 63:124-130. DOI: 10.1016/j.parkreldis.2019.02.022. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Archer D, Mitchell T, Burciu R, Yang J, Nigro S, Quattrone A . Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism. Mov Disord. 2020; 35(8):1388-1395. PMC: 8316785. DOI: 10.1002/mds.28060. View

Nakano Y, Shimada H, Shinotoh H, Hirano S, Tagai K, Sano Y . PET-based classification of corticobasal syndrome. Parkinsonism Relat Disord. 2022; 98:92-98. DOI: 10.1016/j.parkreldis.2022.04.015. View

Constantinides V, Paraskevas G, Stamboulis E, Kapaki E . Simple linear brainstem MRI measurements in the differential diagnosis of progressive supranuclear palsy from the parkinsonian variant of multiple system atrophy. Neurol Sci. 2017; 39(2):359-364. DOI: 10.1007/s10072-017-3212-2. View

Constantinides V, Paraskevas G, Velonakis G, Toulas P, Karavasilis E, Stefanis L . The "hypointense substantia nigra" sign. A novel MRI marker of progressive supranuclear palsy. J Neurol Sci. 2020; 421:117286. DOI: 10.1016/j.jns.2020.117286. View

Constantinides V, Souvatzoglou M, Paraskevas G, Chalioti M, Stefanis L, Kapaki E . Dopamine transporter SPECT imaging in Parkinson's disease and atypical Parkinsonism: a study of 137 patients. Neurol Sci. 2023; 44(5):1613-1623. DOI: 10.1007/s10072-023-06628-9. View

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

Eraslan C, Acarer A, Guneyli S, Akyuz E, Aydin E, Colakoglu Z . MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy. Neurol Res. 2018; 41(2):110-117. DOI: 10.1080/01616412.2018.1541115. View

10.

Ahn J, Kim M, Kim J, Youn J, Jang W, Oh E . Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome. Parkinsonism Relat Disord. 2019; 66:80-86. DOI: 10.1016/j.parkreldis.2019.07.009. View

11.

Hussl A, Mahlknecht P, Scherfler C, Esterhammer R, Schocke M, Poewe W . Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. Mov Disord. 2010; 25(14):2444-9. DOI: 10.1002/mds.23351. View

12.

Whitwell J, Tosakulwong N, Botha H, Ali F, Clark H, Duffy J . Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. Neuroimage Clin. 2020; 25:102152. PMC: 6961761. DOI: 10.1016/j.nicl.2019.102152. View

13.

Mangesius S, Krismer F, Gizewski E, Muller C, Hussl A, Schocke M . 1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism. Mov Disord. 2016; 31(12):1925-1927. DOI: 10.1002/mds.26823. View

14.

Whitwell J, Lowe V, Tosakulwong N, Weigand S, Senjem M, Schwarz C . [ F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord. 2016; 32(1):124-133. PMC: 5552410. DOI: 10.1002/mds.26834. View

15.

Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P . MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology. 2007; 246(1):214-21. DOI: 10.1148/radiol.2453061703. View

16.

Oliveira Hauer K, Pawlik D, Leuzy A, Janelidze S, Hall S, Hansson O . Performance of [F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy. Parkinsonism Relat Disord. 2022; 106:105226. DOI: 10.1016/j.parkreldis.2022.11.018. View

17.

Gama R, Tavora D, Bomfim R, Silva C, Bruin V, Bruin P . Morphometry MRI in the differential diagnosis of parkinsonian syndromes. Arq Neuropsiquiatr. 2010; 68(3):333-8. DOI: 10.1590/s0004-282x2010000300001. View

18.

Quattrone A, Sarica A, La Torre D, Morelli M, Vescio B, Nigro S . Magnetic Resonance Imaging Biomarkers Distinguish Normal Pressure Hydrocephalus From Progressive Supranuclear Palsy. Mov Disord. 2020; 35(8):1406-1415. DOI: 10.1002/mds.28087. View

19.

Oktay C, Ozkaynak S, Eseroglu E, Karaali K . Contribution of the Mesencephalon Indices to Differential Diagnosis of Parkinsonian Disorders. Can Assoc Radiol J. 2020; 71(1):100-109. DOI: 10.1177/0846537119888411. View

20.

Grijalva R, Pham N, Huang Q, Martin P, Ali F, Clark H . Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. Mov Disord. 2021; 37(4):702-712. PMC: 9018485. DOI: 10.1002/mds.28901. View